Xtent in phase II trial for customisable DES (drug-eluting stent)
This article was originally published in Clinica
Executive Summary
The Menlo, Park, California company, Xtent, has begun enrolling up to 100 patients in its CUSTOM II trial of a modular drug-eluting stent (DES) system that allows cardiologists to customise the stent length to match the patient's lesion. After deployment of the sheath-covered Xtent system, the cardiologist decides how many of the 4mm segments are needed to span the target lesion, retracts the sheath, detaches the correct length stent and then expands the stent with the integrated balloon.